Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

@article{Gamis2014GemtuzumabOI,
  title={Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.},
  author={Alan S Gamis and Todd A Alonzo and Soheil Meshinchi and Lillian Sung and Robert B. Gerbing and Susana C. Raimondi and Betsy Hirsch and Samir B Kahwash and Amy Heerema-McKenney and Laura J Winter and Kathleen Glick and Stella M. Davies and Patti Byron and Franklin O. Smith and Richard Aplenc},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 27},
  pages={3021-32}
}
PURPOSE To improve survival rates in children with acute myeloid leukemia (AML), we evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against CD33, as an alternative to further chemotherapy dose escalation. Our primary objective was to determine whether adding GO to standard chemotherapy improved event-free survival (EFS) and overall survival (OS) in children with newly diagnosed AML. Our secondary objectives examined outcomes by risk group and method of intensification… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS